Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Gains from Sales and Divestitures (2024 - 2025)

Historic Gains from Sales and Divestitures for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $28125.0.

  • Prelude Therapeutics' Gains from Sales and Divestitures fell 1176.47% to $28125.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $28125.0, marking a year-over-year decrease of 1176.47%. This contributed to the annual value of $42500.0 for FY2024, which is N/A changed from last year.
  • Prelude Therapeutics' Gains from Sales and Divestitures amounted to $28125.0 in Q3 2025, which was down 1176.47% from $18750.0 recorded in Q2 2025.
  • Prelude Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $42500.0 during Q4 2024, with a 5-year trough of $9375.0 in Q1 2025.